Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 240 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR Five-Year Survival Outcomes with Neoadjuvant Therapy in Melanoma Demonstrate that Neoadjuvant ICIs Exceeded Adjuvant Benchmarks Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib MOST POPULAR With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era June 11, 2020 A bug in the system – the difficulties of linking the... June 2, 2021 Getting cancer services back on track during the COVID-19 pandemic June 22, 2020 Foodie Friday: Butternut Squash Macaroni Casserole September 24, 2021 Load more HOT NEWS MAP Congress 2020: Molecular Analysis for Precision Oncology New Treatments for Non-Small Cell Lung Cancer With an EGFR Mutation:... How to Talk About Advanced Cancer Care Planning: An Expert Discussion New Research Discovers How Scalp Cooling Helps Chemo Patients Keep Their...
